Apollomics Inc. (APLM) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Apollomics Inc. Do?
N/A Apollomics Inc. (APLM) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO N/A. With a market capitalization of $32M, APLM is one of the notable companies in the Healthcare sector.
Apollomics Inc. (APLM) Stock Rating — Reduce (April 2026)
As of April 2026, Apollomics Inc. receives a Reduce rating with a composite score of 38.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.APLM ranks #2,634 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Apollomics Inc. ranks #351 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
APLM Stock Price and 52-Week Range
Apollomics Inc. (APLM) currently trades at $13.60. The stock lost $1.25 (8.4%) in the most recent trading session. The 52-week high for APLM is $42.12, which means the stock is currently trading -67.7% from its annual peak. The 52-week low is $3.66, putting the stock 271.7% above its annual trough. Recent trading volume was 100K shares, suggesting relatively thin trading activity.
Is APLM Overvalued or Undervalued? — Valuation Analysis
Apollomics Inc. (APLM) carries a value factor score of 5/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2859.55x, versus the sector average of 2.75x.
At current multiples, Apollomics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Apollomics Inc. Profitability — ROE, Margins, and Quality Score
Apollomics Inc. (APLM) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1958472.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1644.8% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
APLM Debt, Balance Sheet, and Financial Health
Apollomics Inc. has a debt-to-equity ratio of 8782.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. Total debt on the balance sheet is $966,000. Cash and equivalents stand at $10M.
APLM has a beta of 0.42, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Apollomics Inc. is 37/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Apollomics Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Apollomics Inc. reported revenue of $0. Net income for the quarter was $-54M. Operating income came in at $-55M.
In FY 2024, Apollomics Inc. reported revenue of $0. Net income for the quarter was $-54M. Operating income came in at $-55M.
In FY 2023, Apollomics Inc. reported revenue of $0. Net income for the quarter was $-99M. Operating income came in at $-55M.
In FY 2022, Apollomics Inc. reported revenue of $0. Net income for the quarter was $-50M. Operating income came in at $-45M.
Over the past 5 quarters, Apollomics Inc. has experienced revenue contraction from $0 to $0. Investors analyzing APLM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
APLM Dividend Yield and Income Analysis
Apollomics Inc. (APLM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
APLM Momentum and Technical Analysis Profile
Apollomics Inc. (APLM) has a momentum factor score of 66/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 62/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 28/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
APLM vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Apollomics Inc. (APLM) ranks #351 out of 838 stocks based on the Blank Capital composite score. This places APLM in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing APLM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full APLM vs S&P 500 (SPY) comparison to assess how Apollomics Inc. stacks up against the broader market across all factor dimensions.
APLM Next Earnings Date
No upcoming earnings date has been announced for Apollomics Inc. (APLM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy APLM? — Investment Thesis Summary
The quantitative profile for Apollomics Inc. suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 5/100 indicates premium valuation. Price momentum is positive at 66/100, suggesting the trend favors buyers. High volatility (stability score 37/100) increases portfolio risk.
In summary, Apollomics Inc. (APLM) earns a Reduce rating with a composite score of 38.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on APLM stock.
Related Resources for APLM Investors
Explore more research and tools: APLM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare APLM head-to-head with peers: APLM vs AZN, APLM vs SLGL, APLM vs VMD.